Last updated: September 4, 2026
The naloxone hydrochloride/pentazocine hydrochloride combination is a mature, low-growth opioid analgesic product sold primarily as a generic oral tablet. The U.S. product contains 50 mg pentazocine hydrochloride and 0.5 mg naloxone hydrochloride per tablet. Its commercial rationale is abuse deterrence: naloxone has limited effect when taken orally as directed but can reduce opioid effects if the tablet is crushed and injected [1].
The product has no meaningful remaining U.S. composition-of-matter exclusivity, no material Orange Book patent barrier, and no biosimilar exposure. Revenue potential is limited by declining use of pentazocine, generic price competition, controlled-substance compliance costs, and competition from nonopioid analgesics, conventional opioid products, and naloxone rescue products.
What is the naloxone hydrochloride and pentazocine hydrochloride product?
The combination is marketed historically under the brand name Talwin NX and as generic pentazocine and naloxone tablets. Pentazocine is a centrally acting opioid analgesic with mixed agonist-antagonist pharmacology. Naloxone is an opioid antagonist included at a low dose to reduce misuse by nonoral routes [1].
| Product characteristic |
U.S. status |
| Active ingredients |
Pentazocine hydrochloride and naloxone hydrochloride |
| Common strength |
50 mg/0.5 mg tablet |
| Dosage form |
Immediate-release oral tablet |
| Primary indication |
Management of pain severe enough to require an opioid analgesic |
| Regulatory category |
Prescription drug; pentazocine-containing products are controlled substances |
| Brand history |
Talwin NX |
| Current market structure |
Generic and legacy-brand supply |
| Biosimilar relevance |
None |
| Rescue-naloxone equivalence |
None; this is not a naloxone overdose-reversal product |
The combination should not be confused with naloxone nasal spray or injectable naloxone. Those products are used to reverse opioid overdose and address a substantially larger public-health market. In the combination tablet, naloxone is a formulation component rather than the principal commercial therapeutic.
How large is the market for pentazocine and naloxone tablets?
The product occupies a small, mature niche in the U.S. opioid market. Public companies generally do not disclose revenue for the combination separately, and the product is not a material reporting segment for major pharmaceutical companies.
Market demand is constrained by four factors:
- Prescribers have shifted toward nonopioid therapies, newer opioid products, and more closely monitored pain-management protocols.
- Pentazocine has lower contemporary prescribing relevance than oxycodone, hydrocodone, tramadol, buprenorphine, and other alternatives.
- Generic substitution compresses price and reduces manufacturer-level revenue.
- The combination has limited differentiation beyond its abuse-deterrence design.
The product retains demand in selected chronic and acute pain settings, including markets where prescribers value a mixed agonist-antagonist opioid. Demand can also persist because some patients are stable on legacy therapy and switching treatment may create clinical or reimbursement friction.
Commercial market profile
| Metric |
Direction |
| Volume |
Low and structurally declining in the U.S. |
| Average selling price |
Generic pricing, generally low relative to branded specialty drugs |
| Revenue growth |
Likely flat to negative over the long term |
| Gross-margin potential |
Can be attractive for a manufacturer with reliable supply and low manufacturing cost |
| Market concentration |
Vulnerable to temporary concentration when suppliers exit |
| Reimbursement |
Generic-drug formulary treatment |
| Prescriber base |
Pain specialists, primary-care physicians, and legacy opioid prescribers |
| Key demand driver |
Continued use by established patients |
| Key risk |
Product discontinuation or intermittent shortage |
A shortage or supplier exit can create temporary price improvement, but that effect is usually a supply event rather than durable market expansion.
What patents protect naloxone hydrochloride and pentazocine hydrochloride?
No significant active U.S. patent estate is expected to block generic manufacture of the immediate-release 50 mg/0.5 mg tablet. The original product patents and early formulation protections are long expired. The FDA Orange Book does not identify a material active patent barrier for the legacy combination product [2].
| Protection category |
Current commercial relevance |
| Pentazocine composition patent |
Expired |
| Naloxone composition patent |
Expired |
| Original combination patent |
Expired or no longer commercially blocking |
| Immediate-release tablet protection |
Expired |
| Method-of-use patents |
No material active barrier identified for the labeled pain indication |
| Orange Book-listed patents |
No meaningful active patent protection identified |
| Pediatric exclusivity |
None of material commercial significance |
| New chemical entity exclusivity |
Expired decades ago |
The absence of active patent protection means competition is governed by FDA approval requirements, manufacturing economics, controlled-substance controls, product quality, and supply reliability rather than exclusionary intellectual property.
What formulations are protected by active patents?
The relevant commercial product is an immediate-release tablet. There is no established active U.S. patent moat around the standard 50 mg/0.5 mg oral formulation. A company could seek protection for a genuinely differentiated dosage form, release profile, abuse-deterrent architecture, or manufacturing process, but such protection would not automatically block existing generic tablets.
Patent value would depend on whether the claimed technology materially changed clinical performance and whether the FDA approved the protected formulation. A narrow process patent would generally provide weaker commercial control than a composition or formulation patent covering the marketed product.
When does naloxone/pentazocine lose exclusivity?
The product lost practical U.S. exclusivity long ago. Talwin NX was approved in the early 1980s, and any original regulatory exclusivity and core patent protection have expired [1, 2].
Exclusivity timeline
| Period |
Event |
| Pre-1980s |
Pentazocine established as an opioid analgesic |
| Early 1980s |
Naloxone/pentazocine combination approved as Talwin NX |
| Following approval |
Brand commercial protection and regulatory exclusivity applied |
| Subsequent decades |
Core patents and exclusivity expired |
| Current period |
Generic competition; no meaningful market exclusivity |
There is no current exclusivity date that would prevent an approved generic from entering the U.S. market.
What is the Orange Book status of Talwin NX and generic pentazocine/naloxone?
The product is an old, small-market prescription drug rather than a modern patent-protected branded product. The Orange Book is relevant for identifying listed patents and reference-listed drug information, but it does not create a new barrier for this combination [2].
A generic applicant would generally rely on an abbreviated new drug application referencing the applicable reference product. Because there is no meaningful active patent estate, a Paragraph IV certification is unlikely to be the central entry issue.
Are there Paragraph IV challenges or patent litigation?
No material, current U.S. Paragraph IV litigation is associated with an active patent estate for the standard naloxone/pentazocine tablet based on the public regulatory record available through June 2024. The main reason is structural: there are few, if any, commercially relevant Orange Book patents left to challenge.
| Litigation issue |
Assessment |
| Active branded patent suit |
No material case identified |
| Paragraph IV exposure |
Low |
| 30-month stay risk |
Low absent a newly listed patent |
| Settlement agreement |
No commercially significant settlement identified |
| Hatch-Waxman dispute |
Unlikely to determine market access |
| Primary legal risk |
Controlled-substance compliance, manufacturing quality, labeling, and supply obligations |
A new formulation could create litigation exposure if a sponsor secured patent protection and listed the patent in the Orange Book. That scenario would concern a new product, not the established immediate-release tablet.
How strong is the patent estate for naloxone/pentazocine?
The patent estate is weak from a market-exclusion perspective and has little residual value for licensing or litigation.
Patent-strength assessment
| Factor |
Rating |
Reason |
| Core composition protection |
Very low |
Historical patents expired |
| Standard tablet formulation |
Very low |
No meaningful active barrier identified |
| Method-of-use protection |
Low |
Mature pain indication |
| Manufacturing know-how |
Moderate |
Controlled-substance handling and quality systems matter |
| Regulatory dossier value |
Low to moderate |
Approval and supply history can support continuity |
| Supply-chain advantage |
Moderate |
Reliable controlled-substance production is valuable in a thin market |
| Litigation leverage |
Very low |
Limited patent basis for exclusion |
| Licensing value |
Low |
No apparent platform or exclusivity asset |
The most defensible commercial asset is not the patent estate. It is a compliant, reliable manufacturing and distribution operation capable of maintaining supply despite a small market and controlled-substance requirements.
What generic entry risks exist?
Generic entry risk is already realized rather than prospective. Multiple suppliers can compete where approved products are available, but the number of active suppliers may be lower than the number of historical approvals.
The principal risks are:
- Further price erosion if additional manufacturers enter.
- Supply interruption if one or more controlled-substance manufacturers withdraw.
- FDA manufacturing or quality action.
- Wholesaler delisting caused by low volume.
- State-level prescribing restrictions affecting opioid utilization.
- Substitution toward buprenorphine, tramadol, nonopioid analgesics, or other pain treatments.
- Reimbursement pressure from generic formulary tiers.
The market can experience a paradoxical pattern: long-term demand declines while short-term pricing rises during shortages. That pattern benefits an incumbent only if it maintains inventory, regulatory compliance, and distribution access.
How does this product compare with naloxone rescue products?
Naloxone rescue products have stronger volume drivers, broader public-health relevance, and greater commercial visibility. The naloxone/pentazocine tablet is a legacy analgesic product in which naloxone is a secondary ingredient.
| Attribute |
Naloxone/pentazocine tablet |
Naloxone rescue product |
| Principal therapeutic purpose |
Pain management |
Opioid overdose reversal |
| Naloxone role |
Abuse-deterrence component |
Active reversal agent |
| Typical route |
Oral |
Intranasal or injectable |
| Market growth |
Mature or declining |
Supported by overdose-response demand |
| Patent opportunity |
Limited for legacy tablet |
Greater for delivery systems and devices |
| Public procurement |
Limited |
Significant in some jurisdictions |
| Generic competition |
Established |
Expanding, but product-specific |
A company seeking growth in naloxone would generally find more attractive opportunities in nasal delivery, autoinjectors, public-access programs, and overdose-response procurement than in the pentazocine combination.
What regulatory and manufacturing barriers affect the market?
The product has low intellectual-property barriers but moderate operational barriers. Pentazocine is subject to controlled-substance requirements, including security, quota, recordkeeping, distribution controls, and compliance with applicable Drug Enforcement Administration rules [3].
Manufacturers must manage:
- Controlled-substance registration and quota allocation.
- Content uniformity for both active ingredients.
- Stability and impurity control.
- Tamper-resistant packaging and labeling requirements where applicable.
- Pharmacovigilance for opioid-related adverse events.
- DEA and FDA inspections.
- Reliable sourcing of two active pharmaceutical ingredients.
- Small-batch economics and inventory carrying costs.
These requirements can discourage new entrants even when patents do not. They also increase the strategic value of a supplier with established regulatory infrastructure.
What is the financial trajectory for manufacturers?
The expected financial trajectory is mature-to-declining revenue with episodic margin improvement during supply disruptions. The product is unlikely to produce material growth without one of three changes:
- A protected new formulation with differentiated clinical or abuse-deterrent performance.
- A supply shortage that temporarily improves pricing.
- A broader commercial strategy that uses the product to support a generic controlled-substance portfolio.
Product-level revenue forecasts should not be based on naloxone rescue-product growth. The combination has different clinical demand, reimbursement, and prescribing dynamics. Its financial value is more closely linked to manufacturing efficiency, market share, supplier continuity, and portfolio synergies.
Key Takeaways
- Naloxone hydrochloride/pentazocine hydrochloride is a mature 50 mg/0.5 mg oral opioid combination, historically sold as Talwin NX.
- Core patent and regulatory exclusivity expired decades ago.
- The FDA Orange Book does not present a material active patent barrier for the standard immediate-release product.
- Paragraph IV litigation and patent-settlement risk are low.
- No biosimilar risk applies because this is a small-molecule drug.
- U.S. revenue is likely low, genericized, and structurally declining.
- Temporary pricing improvement can occur during shortages or supplier exits.
- The principal barriers are controlled-substance compliance, manufacturing quality, supply reliability, and distribution economics.
- Growth prospects are materially weaker than for naloxone nasal spray and other overdose-reversal products.
- The strongest commercial position belongs to a compliant supplier with reliable production, not to a patent owner.
FAQs
Is pentazocine with naloxone still available in the United States?
Yes. The combination has been marketed as Talwin NX and through generic equivalents, although availability can vary by supplier, wholesaler, and pharmacy inventory.
Is naloxone/pentazocine a generic opioid?
Yes. It is an established generic combination product containing the opioid analgesic pentazocine and a low dose of naloxone.
Does the combination prevent opioid addiction?
No. Naloxone may reduce the opioid effect if the product is misused by injection, but it does not eliminate dependence, abuse, overdose, or addiction risk.
Can a company obtain new patents on pentazocine and naloxone?
A company could seek patents on a novel formulation, delivery system, manufacturing process, or abuse-deterrent design if the invention satisfies patentability requirements. Such patents would protect the new technology, not automatically restore exclusivity for the old tablet.
Is Talwin NX commercially more valuable than naloxone nasal spray?
No. Naloxone nasal spray addresses opioid-overdose reversal and has broader demand drivers. Talwin NX is a mature pain product with limited growth and generic pricing.
References
-
U.S. Food and Drug Administration. (n.d.). Pentazocine and naloxone hydrochloride tablets prescribing information. FDA labeling database.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Drug Enforcement Administration. (2024). Controlled substance schedules. https://www.deadiversion.usdoj.gov/schedules/
